Video Experimental Relacionado

Updated: May 1, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 20, 2013

Las paraoxonasas séricas humanas (PON1) Q y R disminuyen selectivamente los peróxidos lipídicos en lesiones

M Aviram¹, E Hardak, J Vaya

¹Lipid Research Laboratory, Technion Faculty of Medicine, the Rappaport Family Institute for Research in the Medical Sciences, Rambam Medical Center, Haifa, Israel. aviram@tx.technion.ac.il

|June 1, 2000

Resumen

Las isoformas Q y R de la paraoxonasa sérica humana (PON1) reducen los peróxidos lipídicos en las lesiones ateroscleróticas. Esta hidrólisis indica que el PON1 es PON1.

Área de la Ciencia:

La bioquímica es la bioquímica.
Ciencias Cardiovasculares Ciencias Cardiovasculares
Enzimología Enzimología.

Sus antecedentes:

La paraoxonasa sérica humana (PON1) exhibe polimorfismo en las posiciones 192 (Q/R) y 55 (M/L).
PON1 juega un papel protector contra la oxidación de las lipoproteínas de baja densidad (LDL), inactivándose durante este proceso.

Objetivo del estudio:

Para comparar los efectos de las isoformas Q y R de PON1 sobre el contenido de peróxido lipídico en lesiones coronarias y carótidas humanas.
Para investigar las actividades enzimáticas de PON1 en el contexto de lesiones ateroscleróticas.

Principales métodos:

Incubación de homogenatos de lesiones coronarias y carotídeas con PON1Q o PON1R.
Medición del contenido de peróxido lipídico y la actividad PON1.
Análisis de los productos de hidrólisis y el efecto de los mutantes PON1.

Principales resultados:

PON1Q y PON1R redujeron los peróxidos lipídicos en lesiones coronarias hasta en un 27% y en lesiones carótidas hasta en un 16%.
La inactivación de PON1Q y PON1R se produjo en un 15% y 45%, respectivamente.
PON1 demostró actividades similares a las de la esterasa y la peroxidasa mediante la hidrólisis y reducción de los hidroperoxidos lipídicos.

Conclusiones:

PON1 hidroliza los peróxidos lipídicos dentro de las lesiones ateroscleróticas humanas.
PON1 exhibe propiedades antiaterogénicas debido a su actividad hidrolizadora de peróxido lipídico.

Más Videos Relacionados

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Quantification of Coenzyme A in Cells and Tissues

Quantification of Coenzyme A in Cells and Tissues

Published on: September 27, 2019

Videos de Conceptos Relacionados

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...